Foster Dykema Cabot & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Foster Dykema Cabot & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$20.6M	Buy	59,357 +42	+0.1%	+$14.7K	2.5%	13
2023 Q2	$20.9M	Buy	59,315 +92	+0.2%	+$31K	2.46%	14
2023 Q1	$18.7M	Buy	59,223 +871	+1%	+$261K	2.4%	16
2022 Q4	$16.9M	Buy	58,352 +14,461	+33%	+$4.41M	2.36%	20
2022 Q3	$12.7M	Buy	+43,891	New	+$12.6M	1.6%	18
2021 Q3	–	Sell	-1,086	Closed	-$219K	–	101
2021 Q2	$219K	Hold	1,086	–	–	0.03%	88
2021 Q1	$233K	Hold	1,086	–	–	0.03%	84
2020 Q4	$257K	Buy	+1,086	New	+$249K	0.04%	85

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Foster Dykema Cabot & Co's VRTX Position: Q3 2023 in Review

Foster Dykema Cabot & Co increased its Vertex Pharmaceuticals (VRTX) stake by 0.07% in Q3 2023, buying an estimated $14.7K and bringing the position to 59,357 shares worth $20.6M. The position accounts for 2.5% of the portfolio, ranked #13.

Foster Dykema Cabot & Co first reported a position in VRTX in Q4 2020 and has held it in 8 quarters since. The position peaked at $20.9M in Q2 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Foster Dykema Cabot & Co held 59,357 shares of Vertex Pharmaceuticals worth $20.6M as of Q3 2023.
Foster Dykema Cabot & Co bought 42 Vertex Pharmaceuticals shares in Q3 2023, an estimated $14.7K.
Vertex Pharmaceuticals made up 2.5% of Foster Dykema Cabot & Co's portfolio in Q3 2023, its #13 holding.
Foster Dykema Cabot & Co first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 8 quarters since.
Foster Dykema Cabot & Co's Vertex Pharmaceuticals position peaked at $20.9M in Q2 2023.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.